Increased p53 immunoreactivity in proliferative inflammatory atrophy of prostate is related to focal acute inflammation

APMIS

Volumn 117, Issue 3, 2009, Pages 185-195

  Wang, Wanzhong ^a   Bergh, Anders ^b   Damber, Jan Erik ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UMEÅ UNIVERSITY   (Sweden)

Author keywords

Immunofluorescence; Immunohistochemistry; Inflammation; P53; Proliferative inflammatory atrophy

Indexed keywords

CYCLOOXYGENASE 2; GLUTATHIONE TRANSFERASE P1; KI 67 ANTIGEN; PROTEIN P53;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA DAMAGE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; NEUTROPHIL CHEMOTAXIS; PRIORITY JOURNAL; PROSTATE DISEASE; PROSTATE HYPERTROPHY; PROSTATE PROLIFERATIVE INFLAMMATORY ATROPHY; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

AGED; ATROPHY; CELL NUCLEUS; CYCLOOXYGENASE 2; EPITHELIAL CELLS; GLUTATHIONE S-TRANSFERASE PI; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEUTROPHILS; PRECANCEROUS CONDITIONS; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; PROSTATITIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 61349167799     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2008.00006.x     Document Type: Article

References (45)

1. Gronberg H, Damber L, Damber JE. Familial prostate cancer in Sweden. A nationwide register cohort study. Cancer 1996 77 : 138 43.
2. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003 349 : 366 81.
3. Daniels NA, Ewing SK, Zmuda JM, Wilt TJ, Bauer DC. Correlates and prevalence of prostatitis in a large community-based cohort of older men. Urology 2005 66 : 964 70.
4. Franks LM. Atrophy and hyperplasia in the prostate proper. J Pathol Bacteriol 1954 68 : 617 21.
5. Shah R, Mucci NR, Amin A, Macoska JA, Rubin MA. Postatrophic hyperplasia of the prostate gland: neoplastic precursor or innocent bystander? Am J Pathol 2001 158 : 1767 73.
6. Ruska KM, Sauvageot J, Epstein JI. Histology and cellular kinetics of prostatic atrophy. Am J Surg Pathol 1998 22 : 1073 7.
7. De Marzo AM, Marchi VL, Epstein JI, Nelson WG. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol 1999 155 : 1985 92.
8. Macoska JA, Trybus TM, Wojno KJ. 8p22 loss concurrent with 8c gain is associated with poor outcome in prostate cancer. Urology 2000 55 : 776 82.
9. Faith D, Han S, Lee DK, Friedl A, Hicks JL, De Marzo AM, et al. p16 is upregulated in proliferative inflammatory atrophy of the prostate. Prostate 2005 65 : 73 82.
10. Wang W, Bergh A, Damber JE. Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium. Prostate 2004 61 : 60 72.
11. Borowsky AD, Dingley KH, Ubick E, Turteltaub KW, Cardiff RD, Devere-White R. Inflammation and atrophy precede prostatic neoplasia in a PhIP-induced rat model. Neoplasia 2006 8 : 708 15.
12. Morris SM. A role for p53 in the frequency and mechanism of mutation. Mutat Res 2002 511 : 45 62.
13. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell 1992 70 : 523 6.
14. Iggo R, Gatter K, Bartek J, Lane D, Harris AL. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990 335 : 675 9.
15. Firestein GS, Echeverri F, Yeo M, Zvaifler NJ, Green DR. Somatic mutations in the p53 tumor suppressor gene in rheumatoid arthritis synovium. Proc Natl Acad Sci USA 1997 94 : 10895 900.
16. Celli A, Que FG, Gores GJ, LaRusso NF. Glutathione depletion is associated with decreased Bcl-2 expression and increased apoptosis in cholangiocytes. Am J Physiol 1998 275 : G749 57.
17. Hibi K, Mitomi H, Koizumi W, Tanabe S, Saigenji K, Okayasu I. Enhanced cellular proliferation and p53 accumulation in gastric mucosa chronically infected with Helicobacter pylori. Am J Clin Pathol 1997 108 : 26 34.
18. Lang SM, Heinzlmann M, Stratakis DF, Teschauer W, Loeschke K. Detection of Ki-ras mutations by PCR and differential hybridization and of p53 mutations by SSCP analysis in endoscopically obtained lavage solution from patients with long-standing ulcerative colitis. Am J Gastroenterol 1997 92 : 2166 70.
19. Tsujimoto Y, Takayama H, Nonomura N, Okuyama A, Aozasa K. Postatrophic hyperplasia of the prostate in Japan: histologic and immunohistochemical features and p53 gene mutation analysis. Prostate 2002 52 : 279 87.
20. Mottaz AE, Markwalder R, Fey MF, Klima I, Merz VW, GN Thalmann, et al. Abnormal p53 expression is rare in clinically localized human prostate cancer: comparison between immunohistochemical and molecular detection of p53 mutations. Prostate 1997 31 : 209 15.
21. Wang W, Bergh A, Damber JE. Increased expression of CCAAT/enhancer- binding protein beta in proliferative inflammatory atrophy of the prostate: relation with the expression of COX-2, the androgen receptor, and presence of focal chronic inflammation. Prostate 2007 67 : 1238 46.
22. Pervin S, Singh R, Chaudhuri G. Nitric oxide-induced cytostasis and cell cycle arrest of a human breast cancer cell line (MDA-MB-231): potential role of cyclin D1. Proc Natl Acad Sci USA 2001 98 : 3583 8.
23. Ohshima H, Bartsch H. Chronic infections and inflammatory processes as cancer risk factors: possible role of nitric oxide in carcinogenesis. Mutat Res 1994 305 : 253 64.
24. Hammond EM, Denko NC, Dorie MJ, Abraham RT, Giaccia AJ. Hypoxia links ATR and p53 through replication arrest. Mol Cell Biol 2002 22 : 1834 43.
25. Hofseth LJ, Hussain SP, Wogan GN, Harris CC. Nitric oxide in cancer and chemoprevention. Free Radic Biol Med 2003 15 : 955 68.
26. Palapattu GS, Sutcliffe S, Bastian PJ, Platz EA, De Marzo AM, Isaacs WB, et al. Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis 2005 26 : 1170 81.
27. Parsons JK, Nelson CP, Gage WR, Nelson WG, Kensler TW, De Marzo AM. GSTA1 expression in normal, preneoplastic, and neoplastic human prostate tissue. Prostate 2001 49 : 30 7.
28. De Marzo AM, Marchi VL, Yang ES, Veeraswamy R, Lin X, Nelson WG. Abnormal regulation of DNA methyltransferase expression during colorectal carcinogenesis. Cancer Res 1999 59 : 3855 60.
29. Pezzella F, Micklem K, Turley H, Pulford K, Jones M, Kocialkowski S, et al. Antibody for detecting p53 protein by immunohistochemistry in normal tissues. J Clin Pathol 1994 47 : 592 6.
30. Brys M, Semczuk A, Wojcik M, Krajewska WM, Jakowicki JA. p53 protein detection by the western blotting technique in normal and neoplastic specimens of human endometrium. Cancer Lett 2000 148 : 197 205.
31. Villuendas R, Piris MA, Orradre JL, Mollejo M, Algara P, Sanchez L, et al. P53 protein expression in lymphomas and reactive lymphoid tissue. J Pathol 1992 166 : 235 41.
32. Wang YC, Lin RK, Tan YH, Chen JT, Chen CY, Wang YC. Wild-type p53 overexpression and its correlation with MDM2 and p14ARF alterations: an alternative pathway to non-small-cell lung cancer. J Clin Oncol 2005 23 : 154 64.
33. Tamboli P, Amin MB, Xu HJ, Linden MD. Immunohistochemical expression of retinoblastoma and p53 tumor suppressor genes in prostatic intraepithelial neoplasia: comparison with prostatic adenocarcinoma and benign prostate. Mod Pathol 1998 11 : 247 52.
34. Zhang XH, Sakamoto H, Takenaka I. Accumulation of p53 and expression of CD44 in human prostatic cancer and benign prostatic hyperplasia: an immunohistochemical study. Br J Urol 1996 77 : 441 4.
35. Schlechte H, Lenk SV, Loning T, Schnorr D, Rudolph BD, Ditscherlein G, et al. p53 tumour suppressor gene mutations in benign prostatic hyperplasia and prostate cancer. Eur Urol 1998 34 : 433 40.
36. Kwak C, Jin RJ, Lee C, Park MS, Lee SE. Thrombospondin-1, vascular endothelial growth factor expression and their relationship with p53 status in prostate cancer and benign prostatic hyperplasia. BJU Int 2002 89 : 303 9.
37. Kinzler KW, Vogelstein B. Cancer-susceptibility genes. Gatekeepers and caretakers. Nature 1997 386 : 763.
38. Cookson MS, Reuter VE, Linkov I, Fair WR. Glutathione S-transferase PI (GST-pi) class expression by immunohistochemistry in benign and malignant prostate tissue. J Urol 1997 157 : 673 6.
39. Lin X, Tascilar M, Lee WH, Vles WJ, Lee BH, Veeraswamy R, et al. GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells. Am J Pathol 2001 159 : 1815 26.
40. Montironi R, Mazzucchelli R, Stramazzotti D, Pomante R, Thompson D, Bartels PH. Expression of pi-class glutathione S-transferase: two populations of high grade prostatic intraepithelial neoplasia with different relations to carcinoma. Mol Pathol 2000 53 : 122 8.
41. Nakayama M, Bennett CJ, Hicks JL, Epstein JI, Platz EA, Nelson WG, et al. Hypermethylation of the human glutathione S-transferase-pi gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: a detailed study using laser-capture microdissection. Am J Pathol 2003 163 : 923 33.
42. Jeronimo C, Usadel H, Henrique R, Oliveira J, Lopes C, Nelson WG, et al. Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J Natl Cancer Inst 2001 93 : 1747 52.
43. De Marzo AM, Meeker AK, Zha S, Luo J, Nakayama M, Platz EA, et al. Human prostate cancer precursors and pathobiology. Urology 2003 62 : 55 62.
44. van Leenders GJ, Gage WR, Hicks JL, van Balken B, Aalders TW, Schalken JA, et al. Intermediate cells in human prostate epithelium are enriched in proliferative inflammatory atrophy. Am J Pathol 2003 162 : 1529 37.
45. Tran CP, Lin C, Yamashiro J, Reiter RE. Prostate stem cell antigen is a marker of late intermediate prostate epithelial cells. Mol Cancer Res 2002 1 : 113 21.